Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Capital Expenditures (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Capital Expenditures for 11 consecutive years, with $36400.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Capital Expenditures rose 24.46% year-over-year to $36400.0, compared with a TTM value of $48834.0 through Sep 2025, down 70.18%, and an annual FY2024 reading of $106189.0, down 37.92% over the prior year.
  • Capital Expenditures was $36400.0 for Q1 2025 at BioRestorative Therapies, up from $12434.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $137674.0 in Q2 2022 and bottomed at -$24605.0 in Q3 2022.
  • Average Capital Expenditures over 4 years is $44527.3, with a median of $36400.0 recorded in 2025.
  • Peak annual rise in Capital Expenditures hit 389.28% in 2024, while the deepest fall reached 82.24% in 2024.
  • Year by year, Capital Expenditures stood at $42581.0 in 2022, then soared by 64.45% to $70024.0 in 2023, then crashed by 82.24% to $12434.0 in 2024, then soared by 192.75% to $36400.0 in 2025.
  • Business Quant data shows Capital Expenditures for BRTX at $36400.0 in Q1 2025, $12434.0 in Q4 2024, and $58459.0 in Q3 2024.